Spyre Completes Enrollment in SKYWAY Trial for Rheumatic Diseases
Event summary
- Spyre Therapeutics completed enrollment in all sub-studies of the SKYWAY basket trial for SPY072 (anti-TL1A) in RA, PsA, and axSpA.
- Topline proof-of-concept data expected in Q3 2026 for RA and Q4 2026 for PsA and axSpA.
- Preclinical data supporting SPY072 presented at the 2026 European Congress of Rheumatology (EULAR).
- SKYWAY and SKYLINE trials on track for six Phase 2 readouts in 2026.
The big picture
Spyre Therapeutics' completion of enrollment in the SKYWAY trial marks a significant milestone in the development of SPY072, an anti-TL1A therapy targeting rheumatic diseases. The rapid enrollment underscores the unmet need in this market and sets the stage for critical data readouts later this year. The company's focus on extended half-life antibodies aligns with broader industry trends toward more durable and convenient treatments in immunology.
What we're watching
- Clinical Efficacy
- Whether SPY072 can demonstrate superior potency and durability in rheumatic diseases.
- Regulatory Pathway
- The pace at which Spyre can advance SPY072 through Phase 2 and potential Phase 3 trials.
- Market Differentiation
- How SPY072's potential quarterly or twice-yearly dosing could position it as a best-in-class therapy.
Related topics